Formosa Pharmaceuticals Investors
Financials
Consolidated Financial Statements
Parent Company Only Financial Statements
News Highlight
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
2023-08-17
TAIPEI – August 16, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with Eyenovia, Inc. (“Eyenovia”, NASDAQ: EYEN), whereby Eyenovia
